Journal of Medical Virology最新文献

{"title":"Correction to “Agreement Between Dried Blood Spot and Plasma PCR in Infants With Congenital Cytomegalovirus Infection”","authors":"","doi":"10.1002/jmv.70325","DOIUrl":"https://doi.org/10.1002/jmv.70325","url":null,"abstract":"<p>M. Shimamura, J. Kim, A. K. Medoro et al., “Agreement Between Dried Blood Spot and Plasma PCR in Infants With Congenital Cytomegalovirus Infection,” <i>Journal of Medical Virology</i>, 97 (2025): e70257. https://doi.org/10.1002/jmv.70257.</p><p>In Table 1, the legend has been modified to denote that numbers in brackets [] indicate interquartile range. The correct table is shown below.</p><p>In Table 4, Column 2 (“Reference #”) has been deleted and replaced by reference numbers added to the first column. The correct table is as follows.</p><p>We apologize for the error.</p>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 4","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.70325","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143707642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dengue Virus Dynamic and Persistence in Body Fluids of Infected Patients in Italy, 2018–2023","authors":"Giulia Matusali,&nbsp;Mattia Manica,&nbsp;Alessandra D'Abramo,&nbsp;Fabrizio Carletti,&nbsp;Gaetano Maffongelli,&nbsp;Francesca Colavita,&nbsp;Piero Poletti,&nbsp;Eleonora Lalle,&nbsp;Giuseppe Sberna,&nbsp;Eliana Specchiarello,&nbsp;Licia Bordi,&nbsp;Silvia Meschi,&nbsp;Gabriella De Carli,&nbsp;Martina Spaziante,&nbsp;Angela Corpolongo,&nbsp;Enrico Girardi,&nbsp;Stefano Merler,&nbsp;Francesco Vairo,&nbsp;Emanuele Nicastri,&nbsp;Fabrizio Maggi,&nbsp;Study Group on Arboviruses","doi":"10.1002/jmv.70322","DOIUrl":"https://doi.org/10.1002/jmv.70322","url":null,"abstract":"<p>Dengue, a mosquito-borne disease caused by the dengue virus (DENV), is constantly expanding worldwide. We investigated the presence and persistence of DENV RNA in the bloodstream and other body fluids to describe the viral kinetics in the human host. We longitudinally collected serum (<i>n</i> = 118), plasma (<i>n</i> = 110), whole blood (<i>n</i> = 90), urine (<i>n</i> = 118), oral swabs (<i>n</i> = 68), saliva (<i>n</i> = 42), semen (<i>n</i> = 23), and vaginal fluids (<i>n</i> = 49) from 42 DENV patients. We measured DENV RNA for a median of 28 (range 1–63) days from symptom onset (DSO). We estimated the probability of viral detection applying a generalized linear model, and the duration of viremia using Monte Carlo-Markov Chain approach. In the bloodstream, the highest rate of positivity, levels of DENV RNA, and persistence were observed in whole blood. The estimated probability of a positive test dropped below 5% after 12.5, 20.7, and 35.4 DSO for plasma, serum, and whole blood, respectively. The average duration of viremia was estimated to be 19.9 DSO. Saliva and oral swabs showed 76.2% and 58.8% of DENV RNA positivity during the first week of symptoms while the longest persistence was observed in urine (39 DSO). DENV was revealed in 20% cervicovaginal (up to 11 DSO) and 30% seminal (up to 35 DSO) fluids. Whole blood represents the preferential specimen for dengue molecular detection and the correct estimation of viremia duration which have clear implications for onward transmission and public health countermeasures. Blood, urine, and oral samples can be assayed according to time from disease onset, severity, and screening purposes.</p>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 4","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.70322","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143707639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Broad Mucosal and Systemic Immunity in Mice Induced by Intranasal Booster With a Novel Recombinant Adenoviral Based Vaccine Protects Against Divergent Influenza A Virus","authors":"Jia Li,&nbsp;Tangqi Wang,&nbsp;Xiaojuan Guo,&nbsp;Yujie Jiang,&nbsp;Liye Jin,&nbsp;Qiaohong Chu,&nbsp;Xuchang Shan,&nbsp;Lingfang Zhang,&nbsp;Ruiwen Han,&nbsp;Chengcheng Zhai,&nbsp;Donghong Wang,&nbsp;Yao Deng,&nbsp;Baoying Huang,&nbsp;Zhuozhuang Lu,&nbsp;Wenjie Tan","doi":"10.1002/jmv.70326","DOIUrl":"https://doi.org/10.1002/jmv.70326","url":null,"abstract":"<div>\u0000 \u0000 <p>The development of broad-spectrum universal influenza vaccines and optimization of vaccination strategies to address the threats posed by pandemics and emerging influenza viruses are critical for public health. In this study, an adenovirus type 5 vector-based influenza vaccine carrying the hemagglutinin (HA) stem of H1, HA stem of H3, and neuraminidase (NA) of N1 from the influenza virus was constructed. Immune responses were evaluated in mice using various vaccination strategies: prime-only (intramuscular [IM] or intranasal [IN]) and prime-boost (IM + IN). Compared with the prime-only strategy, the prime-boost strategy significantly enhanced the systemic immune response, inducing higher levels of antigen-specific IgG, mucosal IgA, and T cell immunity in the spleen and lungs. Furthermore, the IN boosting strategy provided complete protection in mice challenged with the H1N1-PR8, rgH3N2-X31, and rgH5N1-Vietnam viruses, significantly reducing viral loads in the lungs and alleviating lung tissue pathologies. In conclusion, this study elucidates potential avenues for the development and application of universal influenza vaccines using customized mucosal boosting strategies.</p></div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 4","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143707239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sustained Maternal Antibodies Against Parechovirus-A3 During the Coronavirus Disease 2019 Pandemic","authors":"Jun Tachikawa,&nbsp;Yuta Aizawa,&nbsp;Kanako Watanabe,&nbsp;Kazufumi Haino,&nbsp;Koji Nishijima,&nbsp;Akihiko Saitoh","doi":"10.1002/jmv.70313","DOIUrl":"https://doi.org/10.1002/jmv.70313","url":null,"abstract":"<div>\u0000 \u0000 <p>The epidemiology of parechovirus-A3 (PeV-A3) infection in neonates and young infants changed during the coronavirus disease 2019 (COVID-19) pandemic. We hypothesized the pandemic impacted maternal antibodies against PeV-A3. To test this hypothesis, we measured neutralizing antibody titers (NATs) against PeV-A3 in 102 cord blood samples from full-term infants born in June–December 2023 at Niigata University Hospital in Niigata, Japan. Maternal data were collected and compared the findings with our previous pre-pandemic data. The median maternal age was 34.5 years (range: 30–37 years). The geometric mean titer (GMT) against PeV-A3 was 98.4 (95% confidence interval [CI]: 61.7–156.8). The GMT for ages 25–34 years (184.6, <i>n</i> = 45) and 35–44 years (56.3, <i>n</i> = 51) sustained at the same level when we compared to age-matched pre-pandemic data for ages 16–24 years (336.5, <i>n</i> = 11, <i>p</i> = 0.84) and 25–34 years (31.9, <i>n</i> = 107, <i>p</i> = 0.14), respectively. By multivariable logistic regression analyses, maternal age ≤ 34 years was associated with higher seropositivity (adjusted odds ratio [aOR] 3.12, 95% CI 1.18–8.78, <i>p</i> = 0.03). Maternal NATs against PeV-A3 were sustained at the same level during the COVID-19 pandemic, indicating intra-pandemic maintenance of humoral immunity to PeV-A3 in women of childbearing age.</p>\u0000 </div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 4","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extrathymic CD8 and CD4 Double Positive T Cells Presenting Vigorous HBV-Specific Responses Accelerate HBV Clearance","authors":"Zhong Fang,&nbsp;Cong Wang,&nbsp;Chen-lu Huang,&nbsp;Dan Tan,&nbsp;Xiu-hua Peng,&nbsp;Jin-jin Bai,&nbsp;Zheng-hong Yuan,&nbsp;Xiao-yu Yu,&nbsp;Guang-xu Ren","doi":"10.1002/jmv.70303","DOIUrl":"https://doi.org/10.1002/jmv.70303","url":null,"abstract":"<div>\u0000 \u0000 <p>Hepatitis B virus (HBV) infection is a worldwide health problem. Both CD4+ and CD8 + T cells play crucial roles in HBV clearance from acute patients. Nevertheless, an extrathymic CD4 and CD8 double positive T (DPT) cell subset have been reported earlier, the function of these cells in HBV infection is still poorly understood. Herein, peripheral blood mononuclear cells were collected from hepatitis B patients. HBV model mice were established via hydrodynamic injection (HDI) of pAAV-HBV1.2 plasmid. T cells subsets were analyzed with flow cytometry. We found that in acute HBV infection extrathymic DPT cells were significantly increased in acute patients and HDI-based HBV model mice. Unlike thymic DPT cells, these extrathymic DPT cells activated with a CD44 + CD62L+ central memory phenotype. Furthermore, in vitro cultured DPT cells showed the capability to rapidly proliferate and produce multi cytokines after stimulation with HBV peptides. The performance of adoptive transfer depicted that DPT cells were able to migrate into the liver. Immunohistochemistry data from liver biopsies of patients showed that DPT cells were more prone to detection in acute tissue. Purified DPT cells could efficiently kill HBV peptide-loaded hepatocytes in a cytotoxicity assay, and the frequency of DPT cells were reversely correlated with HBV clearance in model mice. Importantly, the transferred DPT cells accelerated the clearance of HBV in mice. Collectively, our study revealed that extrathymic DPT cells are an important immune subset, contributing to viral clearance during HBV infection, which may benefit cure of chronic hepatitis B.</p></div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 4","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143689663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Virus Monitoring in Denmark: A Community-Based Self-Sampling System to Surveil Respiratory Viruses and Associated Symptoms","authors":"Tine Graakjær Larsen,&nbsp;Jonathan R. Ginty,&nbsp;Randi Jessen,&nbsp;Ruben Bjerregaard Nielsen,&nbsp;Anders Jensen,&nbsp;Amanda Bolt Botnen,&nbsp;Bartlomiej Wilkowski,&nbsp;Camilla Rasmussen,&nbsp;Dalila Lepirica Brødbæk,&nbsp;Daniel Steven Shaw,&nbsp;Elias Benameur,&nbsp;Morten Rasmussen,&nbsp;Ramona Trebbien,&nbsp;Shila Mortensen,&nbsp;Stefan S. Olsen,&nbsp;Steven Chong,&nbsp;Tyra Grove Krause,&nbsp;Uffe Vest Schneider,&nbsp;Anne-Marie Vangsted,&nbsp;Nina Ruth Steenhard,&nbsp;Frederik Trier Møller","doi":"10.1002/jmv.70293","DOIUrl":"https://doi.org/10.1002/jmv.70293","url":null,"abstract":"<p>This study presents findings captured in the first 1.5 years of the Virus Monitoring in Denmark (VMD) surveillance system. It describes trends in respiratory viruses, related symptoms, and participant demographics and behaviors. VMD used self-swabbing and self-reported symptoms to monitor respiratory viruses in the general population. Participants were recruited via digital invitations to a representative sample of the population or through workplaces. Symptomatic participants could self-swab and register their samples and report their symptoms via a dedicated smartphone web app. With 30 627 participants and 12 642 samples analyzed, VMD had a broad demographic representation. SARS-CoV-2 was the most frequently detected virus, with positivity rates peaking at over 50% in late 2023. Participants commonly self-swabbed because of fever, cough, and rhinorrhea, with influenza A linked to the highest median number of symptoms. Participants only provided samples after reaching a specific symptom threshold, and participation affected the health-seeking behaviors and work attendance of a few individuals. VMD continuously provided real-time insights into respiratory virus trends and symptomatology in the general non-healthcare-seeking population. Its accessibility – available to anyone with a Danish identification number, a smartphone, and an invitation – highlights its potential as a pandemic preparedness tool.</p>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 4","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.70293","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143689664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe Outcomes From Suspected Human Parvovirus B19 Infection in Immunocompetent Children: The Need for Timely Recognition","authors":"Valentina Ferro,&nbsp;Mara Pisani,&nbsp;Rosaria Marotta,&nbsp;Luana Coltella,&nbsp;Stefania Ranno,&nbsp;Anna Maria Musolino,&nbsp;Sebastian Cristaldi,&nbsp;Chiara Cozzolino,&nbsp;Umberto Raucci,&nbsp;Federica Ferrigno,&nbsp;Cristina Russo,&nbsp;Carlo F. Perno,&nbsp;Alberto Villani","doi":"10.1002/jmv.70324","DOIUrl":"https://doi.org/10.1002/jmv.70324","url":null,"abstract":"<div>\u0000 \u0000 <p>We reported a cluster of 13 previously healthy children who, over a short time frame, received care at a Level III Pediatric Hospital following emergency department (ED) presentations with severe outcomes from suspected human Parvovirus B19 (PVB19) infection, and the presence of PVB19 viremia at presentation. Among these patients, we identified seven cases of myocarditis, one case of acute anterior myocardial infarction due to coronary aneurysms secondary to Kawasaki disease, one case of severe anemia with pancytopenia, two cases of encephalitis, one case of septic shock with meningitis, and one case of septic shock with pancreatitis. Four children required ECMO treatment. One patient succumbed to cardiac shock, while two patients were assisted by the Berlin Heart Support System and remain on the transplant list. After discharge, all patients required ongoing medical assistance, including follow-up care or therapy. This report underscores the importance of prioritizing proactive surveillance by health professionals, focusing not only on monitoring emerging pathogens but also on those that may reemerge with increased aggressiveness in the epidemiological landscape. Additionally, it highlights the need to reassess the risk of severe PVB19 infections in healthy populations.</p>\u0000 </div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 4","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cover Image, Volume 97, Number 3, March 2025","authors":"Ana S. Carvalho,&nbsp;Gean Carlo Pereira-Silva,&nbsp;Julia M. P. Andrade,&nbsp;Wellington S. Ferreira,&nbsp;Gilberto Weissmüller,&nbsp;Elvira M. Saraiva,&nbsp;Andrea T. Da Poian","doi":"10.1002/jmv.70292","DOIUrl":"https://doi.org/10.1002/jmv.70292","url":null,"abstract":"<p><b>Cover Caption:</b> The cover image is based on the article <i>DNA Extracellular Traps Released by Mayaro Virus-Infected Macrophages Act as a Platform for Virus Dissemination</i> by Ana S. Carvalho et al., https://doi.org/10.1002/jmv.70262.\u0000\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 3","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.70292","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143689823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modern Approach to Manage Patients With Kaposi Sarcoma","authors":"Thomas Bettuzzi,&nbsp;Celeste Lebbe,&nbsp;Chloé Grolleau","doi":"10.1002/jmv.70294","DOIUrl":"10.1002/jmv.70294","url":null,"abstract":"<p>Kaposi sarcoma (KS) is a malignancy associated with Kaposi's sarcoma-associated herpesvirus (KSHV), primarily affecting immunocompromised individuals, such as those with HIV or those receiving immunosuppressive treatments. Immunocompetent individuals may also be affected, illustrating the disease's heterogeneity. KS manifests in different forms—classic, endemic, epidemic, iatrogenic, and in men having sex with men—each with distinct clinical features depending on immune status and geographic area of origin. Although advances in treatment have improved disease control, effective management remains a challenge. This review focuses on the comprehensive approach to investigating and treating KS. It highlights the role of histology, immunohistochemistry, and staging in diagnosing KS and assessing disease extension, together with other KSHV diseases (multicentric Castelman disease, primary effusion lymphoma, and KS inflammatory cytokine syndrome<span>)</span>. Treatment strategies are discussed, with emphasis on restoring immunity in immunocompromised patients, alongside conventional local therapies, and chemotherapy options like liposomal doxorubicin and paclitaxel for aggressive and extensive forms. Promising emerging therapies, including immunomodulatory agents, antiangiogenic therapies, and checkpoint inhibitors, are also explored. The review emphasizes the importance of personalized treatment based on the patient's underlying condition and KS subtype. It provides an in-depth look at the pathogenesis, diagnostic methods, and evolving therapeutic approaches, offering valuable insights into improving management and outcomes for KS patients.</p>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 3","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.70294","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143677125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Macrophage-Mediated Delivery of miR-34a-5p-Nanoparticles for Pathogenic Inhibition of Kaposi's Sarcoma-Associated Herpesvirus","authors":"Lixia Yao,&nbsp;Qing Zhang,&nbsp;Xingxing Gao,&nbsp;Fangling Li,&nbsp;Lei Zhang,&nbsp;Jinli Zhang,&nbsp;Wenyi Gu,&nbsp;Xiaohua Tan,&nbsp;Dongmei Li,&nbsp;Dongdong Cao,&nbsp;Yuanming Pan","doi":"10.1002/jmv.70298","DOIUrl":"10.1002/jmv.70298","url":null,"abstract":"<div>\u0000 \u0000 <p>Kaposi's sarcoma-associated herpesvirus (KSHV) has been demonstrated to trigger a variety of malignant neoplasms, however, there are currently no targeted pharmaceutical interventions available. MicroRNA(miRNA)-based antiviral and tumor therapies are frequently utilized, yet the challenges of cellular uptake and susceptibility to degradation underscore the necessity for a delivery system that can effectively combat KSHV. Nonetheless, despite the efficacy of nanocarriers in delivering drugs into cells, they continue to encounter challenges in penetrating the brain. In this study, a macrophage inflammation model was developed to enhance the delivery of miR-34a-5p loaded by folic acid-modified β-cyclodextrin grafted polyethyleneimine (β-CD-PEI-FA) nanocomposites, based on FA targeted to folate receptors on the surface of macrophages and tumor cells. Both in vivo and in vitro safety evaluations of the nanocarriers were performed, which confirmed the exceptional biocompatibility. Assays involving the coculture of induced nanodrug-loaded macrophages and KSHV-positive cells demonstrated the efficient delivery of miR-34a-5p into KSHV-positive cells through macrophages. This delivery led to the inhibition of the proliferation and cell cycle of cocultured KSHV-positive cells, as well as a significant reduction in the expression of KSHV pathogenic genes RTA and v-GPCR. Notably, fluorescence imaging of organs revealed the in vivo delivery of nanocomposites into brain tissues, including tumors. Furthermore, immunohistochemistry analysis revealed increased macrophages infiltration in both tumors and brain tissues in xenograft mice. In conclusion, our study presents a pioneering strategy employing macrophages as carriers for delivering β-CD-PEI-FA/miR-34a-5p nanocomplexes in anti-KSHV therapy.</p></div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 3","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143677051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}